Peking University Medical Technology High-end Medical Equipment Cluster carries out interdisciplinary joint research - successfully achieves

Release date: July 15, 2022 Number of reads:

In the face of the severe situation of the global new coronavirus that continues to rage, it is urgent to develop safe and effective new mechanism drugs that meet clinical needs. Tracing the distribution of SARS-CoV-2 neutralizing antibodies in the body is of great significance to the development of vaccines and special drugs. Recently, the team of Professors Yang Zhi, Zhu Hua, and Han Hongbin from the Institute of Medical Technology, Peking University Health Science Center jointly published a research paper entitled "Evaluation of SARS-CoV-2-neutralizing Nanobody Binding Domain Administered Model Mice" in Research magazine online. The study constructs a new type of targeted neutralizing nanobody probe to achieve real-time monitoring of the virus infection site in the body, providing a technical basis for precision treatment.

Prof. Fudi Wang, deputy editor-in-chief of Research magazine, published a special commentary for this article, pointing out that this study "is expected to be used to determine the RBD residue after infection of organisms, evaluate the therapeutic effects of other neutralizing nanobodies, and guide precision treatment during infection." Liu Song, Ding Lei and Li Guanghui of Shanghai Luoqi Biotechnology from Peking University Cancer Hospital are the co-first authors of the article, and Yang Zhi, Zhu Hua, Han Hongbin and Wan Yakun of Shanghai Luoqi Biotechnology are the co-corresponding authors.

As a double first-class discipline of Peking University, medical technology will continue to promote the concept of cross-integration of medicine, science and engineering, organize joint research in the four major cluster disciplines of medical technology, and contribute to the high-level independent innovation of national medical equipment and technology.

Journal introduction:

"Research" is a world-class, high-impact, comprehensive large-scale OA scientific journal co-founded by the China Association for Science and Technology and the American Association for the Advancement of Science in 2018, benchmarking "Science" and "Nature". The editorial board consists of 174 well-known experts at home and abroad, including 65 academicians from various countries. The editor-in-chief (China) is Bao Weimin, vice chairman of the China Association for Science and Technology and academician of the Chinese Academy of Sciences, and the editor-in-chief (international) is Cui Tianhong, professor at the University of Minnesota.

In June 2022, Research officially received its first impact factor from the Science Citation Index Expanded (SCIE), a subsidiary of Clarivate Analytics in the United States. The first impact factor of Research reached 11.036.

Full text link: https://spj.sciencemag.org/journals/research/aip/9864089/#